| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 76189-0535-60 | 76189-0535 | Ponatinib Hydrochloride | Iclusig | 15.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 14, 2012 | Jul 26, 2020 | No Longer Used |
| 68382-0245-05 | 68382-0245 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 00069-0284-03 | 00069-0284 | Palbociclib | Ibrance | 75.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Mar 30, 2020 | In Use | |
| 60505-6271-01 | 60505-6271 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan 23, 2024 | In Use | |
| 68118-0500-01 | 68118-0500 | Streptozocin | Zanosar | 1.0 g/10mL | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Jul 10, 2025 | In Use | |
| 70748-0208-07 | 70748-0208 | Dasatinib | Dasatinib | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 30, 2026 | In Use | |
| 75007-0501-31 | 75007-0501 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | Dec 17, 2025 | In Use | |
| 42388-0023-36 | 42388-0023 | Cabozantinib | CABOMETYX | 60.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Nov 16, 2017 | In Use | |
| 00409-1704-01 | 00409-1704 | BORTEZOMIB | BORTEZOMIB | 1.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 16, 2022 | In Use | |
| 00085-1519-04 | 00085-1519 | Temozolomide | Temodar | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | In Use | |
| 58181-4102-05 | 58181-4102 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Jan 1, 2025 | In Use | |
| 80978-0111-06 | 80978-0111 | Nelarabine injection | NELARABINE | 250.0 mg/50mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Apr 12, 2023 | In Use | |
| 63020-0040-12 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sep 15, 2021 | Mar 31, 2025 | No Longer Used |
| 10139-0062-02 | 10139-0062 | Methotrexate Sodium | Methotrexate | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous, subcutaneous, intramuscular | May 6, 2013 | Jan 31, 2014 | No Longer Used | |
| 47335-0285-41 | 47335-0285 | Docetaxel Anhydrous | DOCEFREZ | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 3, 2011 | Dec 31, 2016 | No Longer Used | |
| 66993-0236-30 | 66993-0236 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 3, 2024 | In Use | |
| 44567-0530-01 | 44567-0530 | cisplatin | Cisplatin | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Apr 5, 2019 | In Use | |
| 71288-0172-92 | 71288-0172 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 11, 2024 | In Use | |
| 82009-0087-30 | 82009-0087 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 1, 2023 | In Use | |
| 70437-0240-26 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Jul 17, 2017 | In Use | |
| 00409-1060-01 | 00409-1060 | Pemetrexed | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jun 20, 2022 | In Use | |
| 83703-0562-01 | 83703-0562 | PEMETREXED | PEMETREXED | 500.0 mg/50mL | Chemotherapy | Antimetabolite | Folic Acid Analog | INTRAVENTRICULAR | Aug 18, 2022 | In Use | |
| 46708-0730-36 | 46708-0730 | METHOTREXATE | METHOTREXATE | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Jun 4, 2024 | In Use | |
| 62756-0746-60 | 62756-0746 | gemcitabine | INFUGEM | 10.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct 1, 2018 | Jul 31, 2023 | No Longer Used |
| 00703-3427-11 | 00703-3427 | Ifosfamide | Ifosfamide | 1.0 g/20mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jul 26, 2007 | In Use |
Found 12611 results — Export these results
Home